Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Personalis Inc
(NQ:
PSNL
)
1.180
-0.010 (-0.84%)
Streaming Delayed Price
Updated: 11:22 AM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Personalis Inc
< Previous
1
2
3
4
Next >
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
June 18, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
June 13, 2024
From
Personalis, Inc.
Via
Business Wire
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
June 04, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
May 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
May 22, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports First Quarter 2024 Financial Results
May 08, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
March 26, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 19, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis to Participate at Upcoming Investor Conferences
January 31, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
January 30, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
January 16, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
January 05, 2024
From
Personalis, Inc.
Via
Business Wire
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
December 04, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
November 28, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
October 26, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis to Announce Third Quarter 2023 Financial Results
October 24, 2023
From
Personalis, Inc.
Via
Business Wire
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
October 21, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
October 19, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
October 18, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
August 29, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 24, 2023
From
Personalis, Inc.
Via
Business Wire
Personalis Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Personalis, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.